No full-text available
To read the full-text of this research,
you can request a copy directly from the authors.
[The effect of cepharanthin on adjuvant chemotherapy induced bone marrow suppression in patients with breast cancer]
Abstract
We studied the effect of Cepharanthin on bone marrow suppression induced by adjuvant chemotherapy in primary breast cancer patients in our hospital. The 36 patients with breast cancer were divided into two groups. Both groups were administered of MMC 20 mg intravenously on the day of radical operation. One group (23 patients) was administered of Cepharanthin 60 mg every day, but the other (13 patients) group was not administered. In the leukocyte count at 3 weeks after post operation, 82.6% (19 out of 23) of the patients who were administered cepharanthin kept more than 70% of pre-operation's leukocyte. On the other hand, only 46.1% (6 out of 13) of the patients who were not administered Cepharanthin kept more than 70% of pre-operation's leukocyte. The number of thrombocyte was not decreased in both groups. Side effects by Cepharanthin were not observed in this study.
... CEP appears to provide clinical benefits in an astonishing array of medical conditions. Conditions that have been reported to benefit from CEP therapy include radiation-induced leukopenia [4, 55,61,68,69,74] idiopathic thrombocytopenic purpura [32,50], alopecia areata [43], alopecia pityrodes [Cepharanthine package insert, 2008], venomous snakebites and some aspects of cancer [25,53,72]. It has also been suggested that CEP has benefits in the management of HIV [6, 57,58] and malaria [7,71], and may act as an antitumor [3,9,10,13,20,23,26,56,60,79] and anti-allergic agent [2, 12,35,36,38,49]. ...
... Seven full clinical studies involving more than 350 patients have been conducted to examine the benefits of CEP for the control of leukopenia caused by radiation therapy for cancers of the head and neck [55], breast [68,74], and lung [61,69], as well as ovarian [76] and gynecological cancers [4]. The doses utilized in these studies were the following: 50 mg/kg in studies of ovarian and gynecological cancers [4, 76], 60 mg/day in both breast cancer studies [68,74], 1 mg/kg per day for the lung cancer studies [61,69], and 6 mg/kg per day for the study on head and neck cancers [55]. ...
... Seven full clinical studies involving more than 350 patients have been conducted to examine the benefits of CEP for the control of leukopenia caused by radiation therapy for cancers of the head and neck [55], breast [68,74], and lung [61,69], as well as ovarian [76] and gynecological cancers [4]. The doses utilized in these studies were the following: 50 mg/kg in studies of ovarian and gynecological cancers [4, 76], 60 mg/day in both breast cancer studies [68,74], 1 mg/kg per day for the lung cancer studies [61,69], and 6 mg/kg per day for the study on head and neck cancers [55]. CEP was administered intravenously in the ovarian and gynecological cancer studies. ...
Cepharanthine (CEP) is a naturally occurring alkaloid extracted from the plant Stephania cepharantha Hayata. It has been widely used in Japan for more than 40 years to treat a wide variety of acute and chronic diseases. CEP inhibits tumor necrosis factor (TNF)-α-mediated NFκB stimulation, plasma membrane lipid peroxidation and platelet aggregation and suppresses cytokine production. It has also been shown to scavenge free radicals and to have a protective effect against some of the responses mediated by pro-inflammatory cytokines such as TNF-α, interleukin (IL)-1β and IL6. CEP has successfully been used to treat a diverse range of medical conditions, including radiation-induced leukopenia, idiopathic thrombocytopenic purpura, alopecia areata, alopecia pityrodes, venomous snakebites, xerostomia, sarcoidosis, refractory anemia and various cancer-related conditions. No safety issues have been observed with CEP, and side effects are very rarely reported.
... Radiotherapy and chemotherapy, the two primary forms of cancer treatment, inevitably have specific side effects [160]. Cepharanthine has been shown to reduce the toxic side effects of radiation and chemotherapy [114,115] and restore leukopenia [62][63][64][65][66][67][68]161]. It also affects thrombocytopenia [65] and dry mouth [162,163] after radiation and chemotherapy. ...
... Moreover, it enhances the activity of anticancer drugs by disrupting plasma membrane function [147,[241][242][243], increases tumor cell sensitivity [8,43,118,135,[152][153][154][155]160,[244][245][246][247][248][249][250], and reverses multidrug resistance to Adriamycin [9,43,140,150,243,244,251,252], erythromycin [150], vincristine [150], and paclitaxel [151,253]. Furthermore, it also inhibits tumor metastasis by inhibiting cell migration [13,117,126] and is able to treat radiation-induced injuries by reducing damage from chemoradiotherapy [114,115,254], leukopenia [61][62][63][64][65][66][67][68]161,164], thrombocytopenia [65,255], radiation-induced hematopoietic damage [165], and dry mouth [162,163]. ...
Cepharanthine, a natural bisbenzylisoquinoline (BBIQ) alkaloid isolated from the plant Stephania Cephalantha Hayata, is the only bisbenzylisoquinoline alkaloid approved for human use and has been used in the clinic for more than 70 years. Cepharanthine has a variety of medicinal properties, including signaling pathway inhibitory activities, immunomodulatory activities, and antiviral activities. Recently, cepharanthine has been confirmed to greatly inhibit SARS-CoV-2 infection. Therefore, we aimed to describe the pharmacological properties and mechanisms of cepharanthine, mainly including antitumor, anti-inflammatory, anti-pathogen activities, inhibition of bone resorption, treatment of alopecia, treatment of snake bite, and other activities. At the same time, we analyzed and summarized the potential antiviral mechanism of cepharanthine and concluded that one of the most important anti-viral mechanisms of cepharanthine may be the stability of plasma membrane fluidity. Additionally, we explained its safety and bioavailability, which provides evidence for cepharanthine as a potential drug for the treatment of a variety of diseases. Finally, we further discuss the potential new clinical applications of cepharanthine and provide direction for its future development.
... CEP is a biscoclaurine alkaloid extracted from Stephania cepharantha [17]. In a previous clinical study, CEP had effects on adjuvant chemotherapy-induced bone marrow suppression, leukopenia and thrombocytopenia in breast cancer patients [32,33]; however, the anti-tumour effect of CEP on breast cancer is unclear. ...
Background:
Cepharanthine (CEP) is a biscoclaurine alkaloid extracted from Stephania cepharantha and has been shown to have an anti-tumour effect on different types of cancers. However, the anti-cancer effect of CEP on human breast cancer cells is still unclear.
Methods:
We used MTT, clone formation, in vitro scratch, invasion and migration assays to confirm the inhibitory role of CEP on the proliferation of breast cancer cells. Flow cytometry, plasmid construction and western blot analysis were used to study the detailed mechanisms.
Results:
Our study showed that CEP could inhibit cell proliferation by inducing autophagy, apoptosis, and G0/G1 cell cycle arrest of breast cancer cells. Furthermore, we found that CEP induced autophagy and apoptosis by inhibiting the AKT/mTOR signalling pathway.
Conclusion:
We found that CEP could inhibit growth and motility of MCF-7 and MDA-MB-231 breast cancer cell. Our study revealed an anti-tumour effect of CEP on breast cancer cells and suggests that CEP could be a potential new clinical therapy for breast cancer.
... Furthermore, the antitumour effect of adriamycine was improved in the presence of cepharanthine, and it restored the body weight loss observed with adriamycine (Kato and Suzumura, 1987;Asaumi et al., 1995), methylglyoxal bis (Hibasami et al., 1991), vinca alkaloids, such as vincristine, vinblastin, vindesine (Ono and Tanaka, 1997), and immunotoxine (Ohno et al., 2002). This molecule prevented leucopenia in patients treated by radiotherapy (Ohta and Morita, 1990) and chemotherapy (Ushiki et al., 1988;Asukai et al., 1989;Saito et al., 1989;Suzuki et al., 1990;Tsukikawa et al., 1990;Suzuki et al., 1992), reducing the infectious risk period, alleviating taste disorder, and reducing oral discomfort in patients undergoing radiotherapy (Shimazu et al., 2009). ...
... (14,15) Moreover, a dose of 40-100 mg ⁄ body ⁄ day of CEP has been used in several clinical applications such as idiopathic thrombocytopenic purpura (ITP) and in cancer patients without any side effects. (17,35) These findings suggest that CEP is an efficient alternative anticancer agent and that higher dose of CEP can be safely used for cancer patients. ...
Cholangiocarcinoma (CCA) is a major cause of cancer deaths in northeast Thailand. It is aggressive, highly metastatic, and responds poorly to traditional chemotherapy. We demonstrated the potential for Cepharanthine (CEP), a biscoclaurine alkaloid extracted from Stephania cepharantha, to treat CCA. CEP significantly inhibited growth of human CCA cell lines in a dose- and time-dependent manner, regardless of the histologic type of tumor origin. Increasing cell apoptosis via caspase-3 and capase-9 activation was demonstrated in CEP-treated cells. We found that CEP controlled the growth of CCA cells through nuclear factor-kappa B (NF-kappaB) inactivation by inhibiting nuclear translocation. CEP treatment effectively reduced tumor size in CCA-inoculated mice without serious side effects. CEP also increased cell apoptosis in primary histocultures of CCA patients' tissues; this was demonstrated by immunohistochemistry using TUNEL staining. Our results suggest that CEP possesses therapeutic potential against human CCA.
Lymph node status is one of the best prognostic factors in breast cancer, however, its association with distant metastasis is not straightforward. Here we compare molecular mechanisms of nodal and distant metastasis in molecular subtypes of breast cancer, with major focus on luminal A patients. We analyze a new cohort of 706 patients (MMCI_706) as well as an independent cohort of 836 primary tumors with full gene expression information (SUPERTAM_HGU133A). We evaluate the risk of distant metastasis, analyze targetable molecular mechanisms in Gene Set Enrichment Analysis and identify relevant inhibitors. Lymph node positivity is generally associated with NF-κB and Src pathways and is related to high risk (OR: 5.062 and 2.401 in MMCI_706 and SUPERTAM_HGU133A, respectively, p < 0.05) of distant metastasis in luminal A patients. However, a part (≤15%) of lymph node negative tumors at the diagnosis develop the distant metastasis which is related to cell proliferation control and thrombolysis. Distant metastasis of lymph node positive patients is mostly associated with immune response. These pro-metastatic mechanisms further vary in other molecular subtypes. Our data indicate that the management of breast cancer and prevention of distant metastasis requires stratified approach based on targeted strategies.
ResearchGate has not been able to resolve any references for this publication.